A common missense mutation of the methylenetetrahydrofolate reductase (MTHFR) gene (C677T) has been shown to be a risk factor for premature cardiovascular disease and neural tube defect. Deficient activity of MTHFR has also been implicated in the pathogenesis of psychiatric conditions such as schizophrenia and affective disorders. Arinami et al 1 found an increased frequency of homozygosity for the mutated type (T677) of the MTHFR gene in schizophrenia and depression. We tried to replicate this finding in a sample of 343 patients with schizophrenia, 143 with bipolar disorder, 71 with unipolar depression, and 258 controls; however, there was no significantly increased frequency of homozygosity for the T677 allele in any of the diagnostic groups, compared to the controls. Our results suggest that homozygosity for the T677 allele of the MTHFR gene is unlikely to play a major role in the pathogenesis of schizophrenia or affective disorders in our sample.
Methylenetetrahydrofolate reductase (MTHFR; EC 1.5.1.20) catalyses the NADPH-linked reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cofactor for methylation of homocysteine to methionine and a compound which possibly serves as the methylation of biogenic amines. Frosst et al 2 identified a common mutation (C677T), which converts an alanine to a valine residue. This mutation is associated with MTHFR activity and plasma homocysteine levels; homocysteine levels in individuals homozygous for the mutated type were almost twice the value for heterozygous or homozygous for the wild-type. Furthermore, the mutation has been shown to be a risk factor for premature cardiovascular disease 3, 4 and neural tube defect. 5, 6 Deficient activity of MTHFR may also be associated with psychiatric conditions such as mental retardation, schizophrenia, [7] [8] [9] and affective disorders. 10 In line with this, a recent study of Arinami et al 1 examined the C677T polymorphism for patients with schizophrenia, bipolar disorder, and depression, and found an increased frequency of homozygosity for the T677 allele among schizophrenics (odds ratio 1.9, P = 0.0006) and among patients with unipolar depression (odds ratio 2.8, P = 0.005), but not among patients with bipolar disorder (odds ratio 1.0). In the present study, we tried to replicate these findings. Table 1 shows the genotype distribution and allele frequency for the C677T polymorphism of the MTHFR gene among the patients with schizophrenia, bipolar disorder, unipolar depression, and controls. The genotype distributions were in Hardy-Weinberg equilibrium for the four groups ( 2 = 0.1, df = 1, ns for the schizophrenics; 2 = 0.6, df = 1, ns for the patients with bipolar disorder; 2 = 0.7, df = 1, ns for the patients with unipolar depression; 2 = 0.9, df = 1, ns for the controls). The frequency of the T677 allele in our control subjects was 0.38, which was consistent with two other Japanese studies; Nshio et al 11 investigated 129 men aged 40-59 years and obtained an allele frequency of 0.38 and Arinami et al 1 reported 0.37 in their control subjects.
The genotype distributions for the patients with schizophrenia, bipolar disorder, or unipolar depression did not differ significantly from that for the controls ( 2 = 0.8, df = 2, P = 0.67 for the schizophrenics; 2 = 4.3, df = 2, P = 0.12 for the patients with bipolar disorder; 2 = 0.9, df = 2, P = 0.63 for the patients with unipolar depression). When frequency of homozygosity for the T677 allele was compared (see Table 1 ), there was no significant difference between either of the patient groups and the controls, although a trend towards an increased frequency of the homozygosity for the T677 allele was observed in the bipolar patient group (P = 0.09).
The results might have been biased by the differential age distributions between the patients and the controls (see Subjects) because the genotype distribution may be different by the age groups due, at least in part, to premature cardiovascular disease which could lead to shorter life span. We looked into the frequency of homozygosity for the T677 allele for age groups in our total subjects (n = 815, Table 2 ). There was, however, no significant difference in the frequency of homozygosity for the T677 allele by the age groups ( 2 = 1.6, df = 5, P = 0.90). Furthermore, we compared frequency of homozygosity for the T677 allele, excluding subjects who were aged 45 years or more; the remaining subjects were 190 schizophrenics, 59 bipolar patients, 15 unipolar patients, and 236 controls. Again we obtained no significant difference in the frequency of the homozygosity for the T677 allele between any of the patient groups and the controls (P = 0.41 for schizophrenia; P = 0.03 for bipolar disorder; P = 0.18 for unipolar depression), when the critical P-value of 0.017 was used.
We failed to find a significantly increased frequency of homozygosity for the T677 allele of the MTHFR gene in the patients with schizophrenia, bipolar disorder, or unipolar depression compared to the controls. Our results thus do not support the study of Arinami et al 1 who found a significantly increased frequency of homozygosity for the T677 allele of the MTHFR gene in Comparison in the frequency of homozygosity for the T677 allele between each diagnostic group and controls (df = 1). 
schizophrenics and patients with unipolar depression. The sample size in the present study was comparable for schizophrenia, or larger for affective disorders, than that in Arinami et al 1 (297 schizophrenics, 32 patients with major depression, 40 with bipolar disorder, and 419 controls). Although we obtained weak evidence of an increased frequency of homozygosity for the T677 allele in patients with bipolar disorder (P = 0.09 in the total subjects; P = 0.03 in subjects aged less than 45 years), Arinami et al, 1 by contrast, did not find any significant difference in the frequency of homozygosity for the T677 allele between bipolar patients and controls, indicating that our results of moderately increased frequency of homozygosity for the T677 allele in the bipolar group is likely to be attributable to chance.
When homozygosity for the T677 allele was considered to be a risk exposure, the present sample size had a power of 90% to detect an odds ratio of 2.0 for schizophrenics, 2.4 for bipolar, and 2.9 for unipolar patients where the critical P-value was set at 0.05. Although the differential age distribution between each of the patient groups and controls may have biased our results, there was no significant difference in the frequency of homozygosity for the T677 allele among differential age groups ( Table 2 ), indicating that the possible bias could be minimal. Furthermore, even when subjects aged 45 years or more were excluded, we found no significant difference in the frequency of homozygosity for the T677 allele between any of the diagnostic groups and the controls. However, we could not exclude possible biases due to hidden population stratifications, for example, socio-economic status.
In conclusion, our study obtained no evidence for a major role of the C677T polymorphism of the MTHFR gene in the pathogenesis of schizophrenia, bipolar disorder, or unipolar major depression. For schizophrenia, our results accord with the Berger et al's study 12 which found no significant difference in platelet MTHFR activity between schizophrenic and normal individuals. However, the possibility remains that the polymorphism is related to a small proportion of patients with psychoses. In addition, there are at least 14 mutations reported for the MTHFR gene. [13] [14] [15] These variations apart from the C677T mutation, most of which were less frequent but were associated with more severely deficient enzyme activity, might have effects on vulnerability to psychoses, which was not examined in the present study.
Methods

Subjects
Subjects were 343 patients with schizophrenia (167 men and 176 women), 143 with bipolar disorder (53 and 90; 111 bipolar I and 32 bipolar II), 71 unipolar major depression (25 and 46), and 258 controls (129 and 129). The mean age (standard deviation; s.d.) was 42.2 (12.8) for the schizophrenics, 47.9 (13.6) for the patients with bipolar disorder, 55.2 (14.8) for the unipolar depression, and 31.3 (11.3) for the controls. One hundred and eighty-four patients with schizophrenia were recruited from the general psychiatric clinic of Teikyo University Hospital, Tokyo, and the remaining subjects were from wards of three psychiatric hospitals around the Tokyo Metropolitan area. Patients with affective disorders were from the general psychiatric clinics of Teikyo University Hospital, Showa University Hospital, and Shiga University of Medical Science Hospital. Two hundred and seventy-nine cases (81%) of the schizophrenics, 120 (84%) of the bipolar, and 36 (51%) of the unipolar patients had a history of hospitalization. The mean age of onset was 25.0 (s.d. 8.4) years for the schizophrenics, 34.1 (12.8) for the bipolar, and 44.2 (15.3) for the unipolar patients. Consensus diagnosis by at least two psychiatrists according to the DSM-IV criteria, 16 was made for each patient using non-structured interview (interview by one psychiatrist with one or more observing psychiatrists) and scrutinizing medical records. Controls were recruited from hospital staff and medical students, who were not assessed for psychiatric symptoms by any structured interview method, but showed good social functioning (ie, no history of long-term absence from work or school attendance) and reported themselves to be in good health. All the cases and the controls were unrelated Japanese.
Genotyping
With written informed consent, a blood sample was drawn from each individual. Genomic DNA was extracted from whole blood according to standard procedures. Polymerase chain reaction (PCR) amplification was performed for the polymorphic region of the MTHFR gene by using primers and restriction enzyme HinfI according to Frosst et al. 2 Genotypic data were read blind to the case-control status.
Statistical analysis
The presence of Hardy-Weinberg equilibrium was tested by the 2 test for goodness-of-fit. Frequency of homozygosity for the mutated type (T677) was compared between each diagnostic group and the control group by the 2 test for independence; comparisons for three diagnostic groups were made and the critical Pvalue of 0.017 (0.05/3) was used according to the Bonferroni's correction for multiple testing.
Since the MTHFR gene has been shown to be associated with premature cardiovascular disease, 4 those who were homozygous for the mutated type could be associated with a shorter life span. As there was a marked difference in age distribution between each diagnostic group and the controls in our sample, we looked into genotypic distribution by the age groups. We also compared genotypic distribution for those who were aged less than 45 years; we assumed a priori that individuals aged less than 45 years were free from premature death.
